tiprankstipranks
Tvardi Therapeutics (CH:TVRD)
:TVRD
Switzerland Market
TVRD
Tvardi Therapeutics
RESEARCH TOOLSreports

Tvardi Therapeutics (TVRD) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

TVRD Analyst Ratings

Moderate Buy
8Ratings
Moderate Buy
6 Buy
1 Hold
1 Sell
Based on 8 analysts giving stock ratings to
Tvardi
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TVRD Stock 12 Month Forecast

Average Price Target

―
Based on 8 Wall Street analysts offering 12 month price targets for Tvardi Therapeutics in the last 3 months. The average price target is CHF8.36 with a high forecast of CHF12.19 and a low forecast of CHF2.44. The average price target represents a ― change from the last price of ―.
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
Highest Price TargetCHF12.19Average Price TargetCHF8.36Lowest Price TargetCHF2.44
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on CH:TVRD
Etzer Darout
Barclays
Barclays
CHF2.44
Sell
―
Reiterated
08/07/26
Tvardi Therapeutics (TVRD) Gets a Sell from Barclays
H.C. Wainwright Analyst forecast on CH:TVRD
Sara Nik
H.C. Wainwright
H.C. Wainwright
CHF7.31
Buy
―
Reiterated
07/30/26
Analysts' Top Healthcare Picks: Tvardi Therapeutics (TVRD), Disc Medicine (IRON)
Piper Sandler Analyst forecast on CH:TVRD
Yasmeen Rahimi
Piper Sandler
Piper Sandler
CHF10.56
Buy
―
Upgraded
07/08/26
Tvardi Therapeutics upgraded to Overweight from Neutral at Piper SandlerTvardi Therapeutics upgraded to Overweight from Neutral at Piper Sandler
Raymond James Analyst forecast on CH:TVRD
Ryan Deschner
Raymond James
Raymond James
CHF8.13
Buy
―
Upgraded
07/08/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Tvardi Therapeutics (NASDAQ: TVRD), Resmed (NYSE: RMD) and Zimmer Biomet Holdings (NYSE: ZBH)
BTIG Analyst forecast on CH:TVRD
Julian Harrison
BTIG
BTIG
CHF12.19
Buy
―
Reiterated
07/07/26
Analysts Conflicted on These Healthcare Names: Cooper Co (NASDAQ: COO), Tvardi Therapeutics (NASDAQ: TVRD) and COMPASS Pathways (NASDAQ: CMPS)
JonesTrading Analyst forecast on CH:TVRD
Debanjana Chatterjee
JonesTrading
JonesTrading
CHF9.75
Buy
―
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Tvardi Therapeutics (NASDAQ: TVRD) and Organigram Global (NASDAQ: OGI)
Cantor Fitzgerald Analyst forecast on CH:TVRD
Unknown Analyst
Cantor Fitzgerald
Not Ranked
Cantor Fitzgerald
―
Hold
―
Reiterated
05/11/26
Cantor Fitzgerald Sticks to Their Hold Rating for Tvardi Therapeutics (TVRD)
Oppenheimer Analyst forecast on CH:TVRD
Jay Olson
Oppenheimer
Oppenheimer
CHF8.13
Buy
―
Reiterated
05/11/26
Oppenheimer Sticks to Its Buy Rating for Tvardi Therapeutics (TVRD)
Lucid Capital Analyst forecast on CH:TVRD
Christopher Liu
Lucid Capital
Lucid Capital
CHF4.88
Buy
―
Upgraded
02/04/26
Tvardi Therapeutics upgraded to Buy from Neutral at Lucid CapitalTvardi Therapeutics upgraded to Buy from Neutral at Lucid Capital
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on CH:TVRD
Etzer Darout
Barclays
Barclays
CHF2.44
Sell
―
Reiterated
08/07/26
Tvardi Therapeutics (TVRD) Gets a Sell from Barclays
H.C. Wainwright Analyst forecast on CH:TVRD
Sara Nik
H.C. Wainwright
H.C. Wainwright
CHF7.31
Buy
―
Reiterated
07/30/26
Analysts' Top Healthcare Picks: Tvardi Therapeutics (TVRD), Disc Medicine (IRON)
Piper Sandler Analyst forecast on CH:TVRD
Yasmeen Rahimi
Piper Sandler
Piper Sandler
CHF10.56
Buy
―
Upgraded
07/08/26
Tvardi Therapeutics upgraded to Overweight from Neutral at Piper SandlerTvardi Therapeutics upgraded to Overweight from Neutral at Piper Sandler
Raymond James Analyst forecast on CH:TVRD
Ryan Deschner
Raymond James
Raymond James
CHF8.13
Buy
―
Upgraded
07/08/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Tvardi Therapeutics (NASDAQ: TVRD), Resmed (NYSE: RMD) and Zimmer Biomet Holdings (NYSE: ZBH)
BTIG Analyst forecast on CH:TVRD
Julian Harrison
BTIG
BTIG
CHF12.19
Buy
―
Reiterated
07/07/26
Analysts Conflicted on These Healthcare Names: Cooper Co (NASDAQ: COO), Tvardi Therapeutics (NASDAQ: TVRD) and COMPASS Pathways (NASDAQ: CMPS)
JonesTrading Analyst forecast on CH:TVRD
Debanjana Chatterjee
JonesTrading
JonesTrading
CHF9.75
Buy
―
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Tvardi Therapeutics (NASDAQ: TVRD) and Organigram Global (NASDAQ: OGI)
Cantor Fitzgerald Analyst forecast on CH:TVRD
Unknown Analyst
Cantor Fitzgerald
Not Ranked
Cantor Fitzgerald
―
Hold
―
Reiterated
05/11/26
Cantor Fitzgerald Sticks to Their Hold Rating for Tvardi Therapeutics (TVRD)
Oppenheimer Analyst forecast on CH:TVRD
Jay Olson
Oppenheimer
Oppenheimer
CHF8.13
Buy
―
Reiterated
05/11/26
Oppenheimer Sticks to Its Buy Rating for Tvardi Therapeutics (TVRD)
Lucid Capital Analyst forecast on CH:TVRD
Christopher Liu
Lucid Capital
Lucid Capital
CHF4.88
Buy
―
Upgraded
02/04/26
Tvardi Therapeutics upgraded to Buy from Neutral at Lucid CapitalTvardi Therapeutics upgraded to Buy from Neutral at Lucid Capital
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Tvardi Therapeutics

3 Months
Debanjana ChatterjeeJonesTrading
Success Rate
3/9 ratings generated profit
33%
Average Return
-12.14%
Copying Debanjana Chatterjee's trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -12.14% per trade.
1 Year
Julian HarrisonBTIG
Success Rate
0/6 ratings generated profit
0%
Average Return
-53.73%
Copying Julian Harrison's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -53.73% per trade.
2 Years
Julian HarrisonBTIG
Success Rate
0/6 ratings generated profit
0%
Average Return
-54.97%
Copying Julian Harrison's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -54.97% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TVRD Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
6
6
7
9
6
Buy
0
0
0
0
0
Hold
3
4
4
1
0
Sell
1
2
2
3
3
Strong Sell
0
0
0
0
0
total
10
12
13
13
9
In the current month, TVRD has received 6 Buy Ratings, 0 Hold Ratings, and 3 Sell Ratings. TVRD average Analyst price target in the past 3 months is 8.36.
Each month's total comprises the sum of three months' worth of ratings.

TVRD Financial Forecast

TVRD Earnings Forecast

Next quarter’s earnings estimate for TVRD is -CHF0.57 with a range of -CHF0.95 to -CHF0.33. The previous quarter’s EPS was ―. TVRD beat its EPS estimate 66.67% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.24% of the time in the same period. In the last calendar year TVRD has Outperformed its overall industry.
Next quarter’s earnings estimate for TVRD is -CHF0.57 with a range of -CHF0.95 to -CHF0.33. The previous quarter’s EPS was ―. TVRD beat its EPS estimate 66.67% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.24% of the time in the same period. In the last calendar year TVRD has Outperformed its overall industry.

TVRD Sales Forecast

Next quarter’s sales forecast for TVRD is CHF0.00 with a range of CHF0.00 to CHF0.00. The previous quarter’s sales results were ―. TVRD beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 50.40% of the time in the same period. In the last calendar year TVRD has Performed in-line its overall industry.
Next quarter’s sales forecast for TVRD is CHF0.00 with a range of CHF0.00 to CHF0.00. The previous quarter’s sales results were ―. TVRD beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 50.40% of the time in the same period. In the last calendar year TVRD has Performed in-line its overall industry.

TVRD Stock Forecast FAQ

What is CH:TVRD’s average 12-month price target, according to analysts?
Based on analyst ratings, Tvardi Therapeutics’s 12-month average price target is 8.36.
    What is CH:TVRD’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:TVRD, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Tvardi Therapeutics a Buy, Sell or Hold?
        Tvardi Therapeutics has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 1 hold ratings and 1 sell ratings.
          What is Tvardi Therapeutics’s share price target?
          The average share price target for Tvardi Therapeutics is 8.36. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF12.19 ,and the lowest forecast is CHF2.44. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Tvardi Therapeutics?
            Tvardi Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.
              How can I buy shares of Tvardi Therapeutics?
              To buy shares of CH:TVRD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.